Clinical

Articles

Based on phase 2 data, the FDA granted accelerated approval to melphalan flufenamide in combination with dexamethasone for the treatment of multiple myeloma following 4 or more prior lines of therapy.

FDA Grants Accelerate Approval to Melphalan flufenamide for Heavily Pretreated Myeloma

Results of a phase 2 trial testing the efficacy of idecabtagene vicleucel in patients with heavily pretreated myeloma are reported.

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Data regarding patients with previous Hodgkin lymphoma and primary myelofibrosis diagnoses found associations with subsequent diagnosis of multiple myeloma.

Previous Cancer Diagnoses Associated with Subsequent Development of Multiple Myeloma

Research in the Journal of Clinical Oncology found an association between the combination of daratumumab, lenalidomide, and dexamethasone with improved patient-reported outcomes versus lenalidomide and dexamethasone alone.

Daratumumab Combo Improves PROs for Patients with Newly Diagnosed MM

Videos

The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.

Deepu Madduri, MD, on the Future Potential of Therapies to Treat Multiple Myeloma 

Data published in The Lancet found a favorable tolerability profile for the subcutaneous formulation of bortezomib when compared with previous trials of the combination panobinostat plus dexamethasone and intravenous bortezomib in myeloma.

Subcutaneous Bortezomib Combo Improves Tolerability for Patients with Relapsed/Refractory Multiple Myeloma

The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on Next Steps for the CARTITUDE-1 Trial

Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.

Deepu Madduri, MD, on the Implications of the Phase 1b/2 CARTITUDE-1 Trial Results

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial

Hypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.

Multiple Myeloma | Topics